The American Cancer Society announces that the Guardant Health Shield blood test, which was approved by the U.S FDA in 2024, will be included as an option for colorectal cancer screenings amidst a rise in colon cancer cases in young adults.
The American Cancer Society announces that the Guardant Health Shield blood test, which was approved by the U.S. FDA in 2024, will be included as an option for colorectal cancer screenings inthe UnitedStates.
The American Cancer Society adds theFDA-approved Guardant Health Shield blood test toits recommended colorectal cancer screeningoptions in the United Statesamidstariseincoloncancercasesinyoungadults.